Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Nieuwegein – page 165

2 029 clinical trials in Nieuwegein, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Nieuwegein at a glance
2 029
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 029 trials in Nieuwegein

Open in trial search

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Bronchiectasis

Not recruiting

Study on Long-Term Safety and Efficacy of BI 1291583 in Patients with Bronchiectasis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Traumatic pain

Not recruiting

Study on Fentanyl and Esketamine for Pain Relief in Patients with Acute Traumatic Pain

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Sodium
  • Sponsor:Amsterdam UMC Stichting

Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study on Long-term Safety and Efficacy of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Malignant melanoma+1

Not recruiting

Study of 89Zirconium-labeled ipilimumab distribution in patients with metastatic melanoma receiving ipilimumab/nivolumab combination therapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ipilimumab
  • Sponsor:Amsterdam UMC Stichting

Craniocerebral injury

Not recruiting

Study on the Safety and Effectiveness of C1 Esterase Inhibitor and Sodium Chloride for Patients with Traumatic Brain Injury

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Pancreatic carcinoma

Not recruiting

Study comparing FOLFIRINOX versus gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Acute myeloid leukaemia+1

Not recruiting

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Nieuwegein

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on idiopathic pulmonary fibrosis and related conditions, evaluating new therapeutic approaches for lung diseases. Studies include assessment of novel treatments for systemic autoimmune rheumatic diseases with lung involvement.

  • Pulmonary Fibrosis Treatment
  • Interstitial Lung Disease
  • Rheumatic Disease-Related Lung Conditions

Multiple trials are investigating both targeted therapies and comprehensive treatment approaches.

02 Oncology Research

Comprehensive studies in cancer treatment, particularly focusing on prostate cancer and urothelial cancer. Advanced imaging techniques and novel therapeutic combinations are being evaluated for improved patient outcomes.

  • Advanced Colorectal Cancer
  • Acute Myeloid Leukemia
  • Bladder Cancer Therapeutics

Trials are exploring personalized treatment approaches and innovative drug combinations.

03 Neurological Disorders

Research initiatives addressing status epilepticus and post-cardiac arrest care. Studies include innovative approaches for treating dementia and related behavioral issues.

  • Post-Cardiac Arrest Care
  • Dementia Management
  • Stroke Prevention

Investigations focus on both acute neurological conditions and long-term management strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.